Haemostats Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Thrombin Based Hemostats, Oxidized Regenerated Cellulose Based Haemostats, Combination Hemostats, Others), By Formulation (Matrix & Gel Hemostats, Sponge Hemostats, Powder Hemostats, Others), By Application (Orthopedic Surgery, General Surgery, Neurological Surgery, Cardiovascular Surgery, Others), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Casualty Care Centers, Others) and Region Forecast 2020-2031

Hemostats Market size was valued at US$ 2,850.5 million in 2024 and is expected to reach US$ 4,429.6 million by 2031, growing at a significant CAGR of 6.5% from 2025-2031. Moreover, the U.S. Hemostats Market is projected to grow at 6.3% CAGR over the forecast period. The market refers to the global industry focused on products designed to control bleeding during surgical procedures, trauma cases, and emergency care. These products include mechanical, active, and flowable hemostatic agents that aid rapid blood coagulation and support better surgical outcomes. Hemostats are widely used across specialties such as cardiovascular, orthopedic, general surgery, and neurology to enhance patient safety and reduce operative complications.

This market encompasses both natural and synthetic hemostatic materials, including gelatin-, collagen-, oxidized regenerated cellulose–based agents, and thrombin-based products. It also includes innovative combination hemostats that integrate multiple mechanisms to optimize bleeding control. The definition further extends to manufacturing, distribution, and technological development processes supporting advancements in surgical care. The market is experiencing steady growth driven by rising surgical volumes, increasing trauma cases, and a growing preference for minimally invasive procedures that require precise bleeding control. Hospitals and specialty clinics are expanding their adoption of advanced hemostatic agents to reduce surgery time, minimize blood loss, and improve recovery outcomes. Additionally, aging populations and the rising incidence of chronic diseases contribute to increased demand for surgical interventions, supporting market expansion.

Facts and Figures

• Hemostatic sprays—one class of hemostat product—are estimated to be valued around US$ 2.99 billion in 2025, with projections to exceed US$ 5.5 billion by 2032, reflecting strong adoption in surgical bleeding control tools.
• Technological innovation is accelerating surgical hemostatic tools (e.g., sprays, pads), responding to increased minimally invasive surgical volumes and demand for rapid bleeding management in trauma and operative settings.

Key Developments:

• In April 2025, Baxter expanded its Hemopatch Sealing Hemostat offering a ready-to-use, absorbable collagen pad that can be stored at room temperature enhancing convenience and OR readiness in both open and minimally invasive procedures in Europe.
• In May 2025, Merit Medical acquired Biolife Medical for about $120 million, boosting its hemostatic device portfolio with products like StatSeal and WoundSeal aimed at a ~US$ 350 million opportunity segment.

Hemostats Market Segmentation:

Based on the type:

• Thrombin Based Hemostats
• Oxidized Regenerated Cellulose Based Hemostats
• Combination Hemostats
• Others

The thrombin-based hemostats are anticipated to lead the market, driven primarily by their superior clinical effectiveness in rapid bleeding control. The key driver supporting this leadership is their ability to directly accelerate the natural coagulation cascade, enabling faster and more reliable hemostasis across a wide range of surgical procedures. Thrombin-based products are highly valued in complex and high-risk surgeries, such as cardiovascular, orthopedic, and neurosurgical interventions, where precise and immediate bleeding management is critical. Their versatility, ease of application, and proven performance in both open and minimally invasive surgeries further strengthen adoption rates.

Additionally, increasing surgical volumes globally, coupled with rising awareness among surgeons regarding advanced hemostatic solutions, continue to favor thrombin-based hemostats over other types. As healthcare systems emphasize reduced operative time, lower complication rates, and improved patient outcomes, thrombin-based hemostats are expected to maintain their dominant position, making clinical efficacy the most influential driver shaping this segment’s market leadership.

Based on the formulation:

• Matrix & Gel Hemostats
• Sponge Hemostats
• Powder Hemostats
• Others

The matrix and gel hemostats are anticipated to lead the market, primarily driven by their superior adaptability across diverse surgical applications. The single most influential driver behind this dominance is their ability to conform effectively to irregular wound surfaces, ensuring targeted and efficient bleeding control. Matrix and gel formulations can easily fill complex tissue geometries, which enhances clot formation and reduces the risk of rebleeding, making them especially valuable in minimally invasive, laparoscopic, and high-precision surgeries. Their ease of handling and controlled application allow surgeons to achieve hemostasis quickly without excessive pressure or additional devices.

Furthermore, these formulations often provide a favorable balance between mechanical support and biological activity, improving procedural efficiency and patient outcomes. As surgical techniques continue to advance toward precision-based and minimally invasive approaches, the demand for adaptable and reliable hemostatic solutions is rising. Consequently, the versatility-driven clinical preference for matrix and gel hemostats is expected to remain the leading force shaping this segment of the market.

Based on the formulation:

• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Others

The orthopedic surgery is anticipated to represent the leading segment in the market, driven primarily by the high volume of procedures associated with bone and joint disorders. The single most significant driver supporting this leadership is the increasing global incidence of orthopedic conditions, including osteoarthritis, trauma-related injuries, and age-related degenerative diseases, which necessitate surgical intervention. Orthopedic surgeries often involve extensive soft tissue and bone manipulation, resulting in substantial bleeding risks that require effective hemostatic management. As a result, surgeons strongly rely on advanced hemostats to control bleeding, improve surgical visibility, and reduce postoperative complications.

Additionally, the rising elderly population and growing demand for joint replacement and spinal surgeries further amplify the need for reliable hemostatic solutions in this field. With healthcare systems focusing on faster recovery times, reduced blood loss, and improved surgical outcomes, orthopedic surgery continues to drive consistent demand, positioning it as the leading application segment within the overall market.

Based on the end user:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Casualty Care Centers
• Others

The hospitals and clinics are anticipated to lead the market, driven primarily by their high concentration of surgical procedures across multiple specialties. The single most influential driver behind this dominance is the consistently higher patient inflow requiring both elective and emergency surgeries, which significantly increases the demand for effective hemostatic solutions. Hospitals and clinics are equipped with advanced surgical infrastructure, specialized operating rooms, and skilled healthcare professionals, enabling the routine use of hemostats in complex procedures such as cardiovascular, orthopedic, neurological, and general surgeries.

Additionally, these settings manage trauma cases and high-risk patients where rapid bleeding control is critical, further reinforcing reliance on hemostatic products. The availability of better reimbursement frameworks and stronger procurement capabilities also supports the adoption of advanced and premium hemostats in hospitals and clinics. As surgical volumes continue to rise globally and healthcare systems prioritize improved clinical outcomes, hospitals and clinics are expected to remain the leading end-user segment in the market.